NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1144859463 DO
Verify on CMS → Sara Shteyman, DO
Endocrinology, Diabetes & Metabolism Physician in New Britain, Connecticut.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 8,078 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
384
Medicare Part D claims · 85 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
36%
generic claims · 56% brand-name · higher generic rates reduce patient out-of-pocket costs
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Sara Shteyman, DO filed 384 Medicare Part D claims in 2024 as an Endocrinology, Diabetes & Metabolism Physician in New Britain, Connecticut, prescribing 36% generic.
- 384
- Part D claims, 2024
- 36%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥56th
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Sara Shteyman, DO
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1144859463), first enumerated 04/07/2020.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 384 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1144859463 · Endocrinology, Diabetes & Metabolism Physician
NPI-10 · ENUM-RECENT · TAX-MID · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1144859463
- ENUM-RECENT 2020
- TAX-MID 8K Endocrinology, Diabetes
- RX-LIGHT 384
- BOOK-THIN 166 in Connecticut
- PHOTO-ENUM Ivania Salinas, MD · 2020
Sara Shteyman, DO's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
384 ≥ 56th percentile 56% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Sara Shteyman, DO practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Sara Shteyman, DO?
Quality data not reportedPrimary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
384 86% vs specialty avg
Specialty distribution in Connecticut
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Connecticut providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Endocrinology, Diabetes & Metabolism Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1144859463 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | DO |
| Gender | Female |
| NPI Issued | 04/07/2020 |
Hospital and facility affiliations
Facilities where Sara Shteyman, DO bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
The Hospital OF Central Connecticut AT New Britain General And Bradley
New Britain, CT
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Brand vs generic prescribing mix · Brand-heavy
Sara Shteyman, DO - brand share 56.0%
Endocrinology, Diabetes & Metabolism Physician average
56% brand-name claims vs 36% generic, on 384 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
384
Total Claims
$142K
Total Drug Cost
85
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 741.133
- Total Day Supply
- 21,451
- Brand vs Generic
- 56% brand / 36% generic
- Brand Drug Cost
- $138K
- Generic Drug Cost
- $2K
Patient Demographics
- Average Patient Age
- 65.4 years
- Avg HCC Risk Score
- 1.88
- Gender Split
- 65% female / 35% male
- Age Distribution
- <65: 22, 65-74: 43, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Sara Shteyman, DO prescribes most
Top Medicare Part D drugs by claim count, 2024
- Levothyroxine Sodium
Levothyroxine Sodium
53 claims
- Jardiance
Jardiance
28 claims
- Ozempic
Ozempic
24 claims
- Lantus Solostar 19
Lantus Solostar
19 claims
- Alendronate Sodium 18
Alendronate Sodium
18 claims
- Humalog Kwikpen U-… 16
Humalog Kwikpen U-100
16 claims
- Mounjaro 15
Mounjaro
15 claims
- Farxiga 13
Farxiga
13 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 53 |
| Jardiance Empagliflozin | 28 |
| Ozempic Semaglutide | 24 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 19 |
| Alendronate Sodium | 18 |
| Humalog Kwikpen U-100 Insulin Lispro | 16 |
| Mounjaro Tirzepatide | 15 |
| Farxiga Dapagliflozin Propanediol | 13 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 13 |
| Trulicity Dulaglutide | 13 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in CT →
All providers in Connecticut →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Sara Shteyman, DO fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
8,078
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,739
Avg Claims per Provider
Sara Shteyman, DO's 384 claims are below the specialty average of 2,739.
Nationwide Endocrinology, Diabetes & Metabolism Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Shteyman, both outside Connecticut so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2020)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Connecticut
Other clinicians with the same primary specialty enrolled in Connecticut, drawn from the same CMS NPPES roster as Shteyman.
One of 166 Endocrinology, Diabetes & Metabolism Physician providers enrolled in Connecticut, 5 are shown here.
Dr. Fadi Al-Khayer
MD
Storrs, CT
Dr. Vivek Alaigh
MD
Stamford, CT
Dr. Kenda Alkwatli
MD
Wethersfield, CT
Dr. Ipek Alpertunga
MD
Hartford, CT
Dr. Helen Anaedo
M.D
Plainville, CT
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Sara Shteyman, DO's specialty? ▼
Sara Shteyman, DO specializes in Endocrinology, Diabetes & Metabolism Physician and practices in New Britain, Connecticut. Credentials: DO.
How much does Sara Shteyman, DO prescribe under Medicare Part D? ▼
In 2024, Sara Shteyman, DO wrote 384 Medicare Part D claims totaling $142K in drug costs for 85 beneficiaries.
Where is Sara Shteyman, DO located? ▼
Sara Shteyman, DO is located at 100 GRAND ST, New Britain, CT, 06052. Phone: (860) 224-5661.
What is Sara Shteyman, DO's NPI number? ▼
Sara Shteyman, DO's National Provider Identifier (NPI) is 1144859463, issued on 04/07/2020.
Does Sara Shteyman, DO prescribe more brand-name or generic drugs? ▼
Sara Shteyman, DO's prescribing is 56% brand-name and 36% generic drugs by claim count, with $138K in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 8,078 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,739 Medicare Part D claims per year.
What drugs does Sara Shteyman, DO prescribe most often? ▼
Based on 2024 Medicare Part D data, Sara Shteyman, DO's most frequently prescribed drugs include Levothyroxine Sodium, Jardiance, Ozempic. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Sara Shteyman, DO accept Medicare? ▼
Sara Shteyman, DO appears in CMS Medicare data with 384 Part D claims and 85 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Sara Shteyman, DO's credentials? ▼
Sara Shteyman, DO's NPI is 1144859463 with credentials DO. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.